



ISSN: 2410-1397

Master Project in Applied Mathematics

A MATHEMATICAL MODEL FOR THE EFFECTS OF DRUG ABUSE IN TRANSMISSION OF HIV/AIDS IN TURKANA COUNTY

Research Report in Mathematics, Number 08, 2020

LOKARAN ELIZABETH

December 2020



A MATHEMATICAL MODEL FOR THE EFFECTS OF DRUG ABUSE IN TRANSMISSION OF HIV/AIDS IN TURKANA COUNTY

Research Report in Mathematics, Number 08, 2020

LOKARAN ELIZABETH

School of Mathematics
College of Biological and Physical sciences
Chiromo, off Riverside Drive
30197-00100 Nairobi, Kenya

Master Thesis

Submitted to the School of Mathematics in partial fulfilment for a degree in Master of Science in Applied Mathematics

Abstract

Drugs and substance misuse has been recognized to have a significant impact on the spread of HIV/AIDS epidemic. We formulate a deterministic model to assess the contribution of drug and substance abuse to the spread of HIV/AIDS disease among adults in Turkana County, Kenya. The basic reproduction number of the model is determined and stability of equilibria analyzed. The disease free equilibrium point is shown to be globally asymptotically stable when its corresponding basic reproduction number is less than unity. The Lyapunov theorem is used to show that the endemic equilibrium point is Globally asymptotically stable when its corresponding reproduction number is greater than unity.

Declaration and Approval

I the undersigned declare that this dissertation is my original work and to the best of my knowledge, it has not been submitted in support of an award of a degree in any other university or institution of learning.

Signature

Date

LOKARAN ELIZABETH

Reg No. I56/11852/2018

In my capacity as a supervisor of the candidate's dissertation, I certify that this dissertation has my approval for submission.

Signature

Date

Dr. Josephine W. Kagunda
School of Mathematics,
University of Nairobi,
Box 30197, 00100 Nairobi, Kenya.
E-mail: jwndirangu@uonbi.ac.ke

Dedication

I dedicate this project to God Almighty my creator, my strong pillar, my source of inspiration, wisdom, knowledge and understanding. He has been the source of my strength throughout this program and on His wings only have I soared. I also dedicate this work to my husband; Akilimo Safari who has encouraged me all the way and whose encouragement has made sure that I give it all it takes to finish that which I have started. To my children Bildad Akilimo, Monique Rapoo, Looyapus Safari and Daisy Napeyok who have been affected in every way possible by this quest. Thank you. My love for you all can never be quantified. God bless you.

Contents

Abstract	ii
Declaration and Approval	iv
Dedication	vii
Figures and Tables	ix
Acknowledgments	x
1 Introduction	1
1.0.1 HIV/AIDS	1
1.0.2 Substance and Drug abuse	1
1.0.3 Relationship between Alcohol, other drugs and HIV/AIDS	1
1.0.4 Statement of the problem	2
1.0.5 Research Objectives	2
1.0.6 Justification of the Study	3
2 Literature Review	4
3 Model Formulation and Analysis	7
3.1 Model Formulation	7
3.2 Model equations	8
3.3 Model Analysis	12
3.3.1 Positivity of solutions	12
3.3.2 Boundedness	14
3.3.3 Existence and Stability of Equilibria	15
3.3.4 Infection-drug free equilibrium Point, E_{HD}	16
3.3.5 Reproduction Number	16
3.3.6 Local stability of the E_{HD}	20
3.3.7 Global stability analysis of E_{HD}	22
3.3.8 Endemic Equilibrium Point, E^*	26
3.3.9 Global stability of drug endemic equilibrium	28
3.3.10 Sensitivity analysis	31
4 Numerical simulations	33
4.0.1 Parameter Estimation	33
4.0.2 Numerical results	34
5 Discussion and Conclusion	41

Figures and Tables

Figures

Figure 1. Population of susceptible..... 35

Figure 2. HIV infected individuals 35

Figure 3. Infected drug users, I_H 36

Figure 4. Dually infected individuals, I_{HD} 36

Figure 5. HIV infectives under treatment, I_{HD} 37

Figure 6. Infected drug users on treatment, T_D 38

Figure 7. Dually infected individuals under treatment, T_{HD} 39

Figure 8. I_H (red) and I_D (black) Populations..... 40

Tables

Table 1. Description of model variables 11

Table 2. Description of model parameters 12

Table 3. parameter values..... 34

Acknowledgments

First and foremost, thanks to God for His sufficient grace throughout my research period.

I owe my deepest gratitude to my supervisor Dr. Josephine W. Kagunda, without her continuous optimism concerning this work, enthusiasm, encouragement and support this study would hardly have been completed.

My appreciation too goes to my employer, the Teachers Service Commission for granting me the study leave to pursue my studies.

Am grateful to my family, Veronica Lokaran (mother), my husband and children for their love, understanding and prayers that kept me going during my research work.

My friends and classmates, Jacob Abuor, Gideon Chelulei, Evance Ochieng, Edwin Njeru, Samwel Pambo, Peter Olonde and Antony Kabaka for their passionate encouragement to complete my work successfully.

Finally, my thanks go to all the people who have supported me to complete the research work directly or indirectly. God bless you all.

Lokaran Elizabeth

Nairobi, 2020.

1 Introduction

1.0.1 HIV/AIDS

HIV is an abbreviation that stands for Human Immuno-deficiency Virus while AIDS stand for Acquired Immune Deficiency Syndrome which is the higher level or the phase of HIV. Human Immunodeficiency Virus attacks the immune system of the human being and weakens the body to attack by other infections. HIV/AIDS is spread from infected individual during sexual intercourse, blood transfusion, through sharp objects such as injectible needles, from mother to child during gestation period and breast suckling that are principal means of its transmission (Fact HIV/AIDS, 2015). There is no medication to treat people if the person currently has HIV status. Nevertheless, identification and active handling of the infected persons in the phase with ARV therapy will prolong time for the infected people to progress to the phase. HIV/AIDS has continued to be an health issue and has so far claimed more than 32 million lives up to now but with increasing access to care, identification, treatment and prevention of opportunistic infections, the effects of the chronic health condition can be minimized. Towards end of 2018, 37 million people were living with HIV/AIDS (WHO.,2019).

1.0.2 Substance and Drug abuse

A drug is any substance that alters the body functioning (Galvez, 2006). Drug abuse is the wrong use of a substance that interferes with both psychological and physical functioning of the body and can disrupt societal order and patterns of behavior (WHO.,2003). Medications that have influence on human mind can include both legal and illegal drugs (NACADA., 2012). Commonly abused drugs are, and not limited to Alcohol, Heroin, Cocaine, 'Marijuana', Tobacco etc. In Kenya 1.5 million people out of which 18,327 injection material consumers were HIV positive in 2016. Currently, HIV/AIDS prevalence in injection substance users who inject drugs stands at 18.3 percent.

1.0.3 Relationship between Alcohol, other drugs and HIV/AIDS

HIV stigma can lead to drug abuse and the converse is also true. The health of the drug user is compromised negatively influenced. This behavior exposes the drug abuser to offense and infectious diseases including HIV/AIDS (CDC.,2000). Drug and alcohol misuse can alter people's judgment and they may take risks that might expose them to the disease which would otherwise not be the case. The risk of HIV/AIDS transmission can also be related to non-injection drug. A case in point is Cocaine and amphetamine-type stimulants

(ATS) that can easily lead to higher risk of irresponsible sexual behavior which consequently lead to contraction of the illness. Methamphetamine, for example was linked to increased irresponsible behavior among the LGBT and heterosexuals. (Manserg., 2005). At the same time cocaine use may promote multiple sexual partners thus increasing likelihood of contracting HIV/AIDS (Edlin et al., 1994).

1.0.4 Statement of the problem

HIV/AIDS is a global pandemic and Kenya is ranked one of the high-burden countries. Kenya together with countries like Mozambique and Uganda are among those with the joint third-largest epidemic in the World, (AVERT.,2019). According to research by WHO report through the MOH in 2019 HIV/AIDS infection in the country indicate positive progress but new infections are still a challenge. Turkana is high incidence cluster-9 of the 47 Counties that contribute 57 percent of all new infections in Kenya(County HIV profile Report, 2014). Building on the previous deterministic models and focusing on subsequent infections, this mathematical model aims at understanding the dynamics of heterosexual transmission of HIV/AIDS in relation to alcohol and substance abuse based on age of young adults in Turkana county, Kenya. We try to answer the question; "Does alcohol and drug use bear an effect on HIV/AIDS transmission among young adults in Kenya?"

1.0.5 Research Objectives

General Objective

To develop a mathematical model that describes heterosexual transmission of HIV/AIDS in presence of drugs among the adults in Turkana county.

Specific Objectives

- To formulate a model on transmission of HIV/AIDS among adults drug abusers
- To deduce ordinary differential equations from the model.
- To determine DFE and EE points
- To compute the basic reproduction number.
- To investigate the local and global stabilities of DFE and EE points
- To Simulate the model

1.0.6 Justification of the Study

The study of co-infections has become an important aspect of social epidemic given its alarming rate especially those arising from opportunistic diseases among HIV/AIDS infected individuals. Against this backdrop we endeavor to model how substance abuse is a major contributor to non-adherence to HIV/AIDS therapy. In this research we present a non-linear model on effect of drugs and substance abuse on HIV/AIDS transmission in Turkana county. We also focus on abuse of alcohol and other drugs then apply the model to secondary data of persons seeking treatment services for HIV/AIDS at Lodwar Referral Hospital in Turkana County. This study will sensitize policy makers in Kenya to focus on integration of drug therapy into HIV/AIDS prevention, care and treatment strategies as they develop mechanism where patients exhibiting substance abuse behaviors can be referred to rehabilitation treatment programs where available to mitigate the adverse effects HIV/AIDS pandemic.

METHODOLOGY

We develop a compartmental model using epidemiological approach and carry out analysis of the model by quantitatively fitting secondary data from Turkana County and infer the model parameters. This basically involves proof of positivity and boundedness of the model solutions, computing disease-free and endemic equilibrium point and their stability analysis, basic reproduction number and carry out simulation using MATLAB ode inbuilt solvers.

2 Literature Review

According to Omondi et al. (2018), Mathematical models are intended to help comprehend how HIV/AIDS spreads in various groups of people around the world. The model explores the degree of treatment, testing and transmission among the population in Kenya. The model accounts for the mix of HIV/AIDS intervention approaches like PrEP, HTC and ART therapy. The research did not consider entry of people who have the infection to the susceptible and also never considered other transmission means routes like in those who inject drugs. This notwithstanding, their outcomes are relevant in formulating time-dependent intervention approaches in curbing HIV/AIDS transmission.

Kok, (2015) formulated a dynamic version of HIV/AIDS therapy continuation of therapy in Vancouver Canada. He constructed a four sub-population, among them men who have sex with men (MSM), intravenous drug users, female sex workers and the general populace. Their work based on primary activities that focus on treatment adherence and retention among the four risky groups. Their outcome never linked optimal resource allocation to ARV therapy adherence. In conclusion they advocated for more resource allocation to testing in high prevalence settings to obtain good data .

Mathematical model developed by Mardhiyah et al., (2012) was on how HIV/AIDS may spread among a community of injecting drug users. They used the basic reproduction number to analyse stability of the model and found out that the probability of HIV/AIDS transmission among those who inject drugs was such that when the reproduction number is greater than one, or otherwise, the disorder may not exist.

Comiskey et al.,(2007) developed a simple compartmental model with non-linear ordinary differential equations to mathematically represent and ascertain the role played treatment and also the recurrence in the dynamics of alcoholism. The analysis was driven by the simple fact that when the possibility of being a user of drugs exceeds the sum of quitting drug use, leading to increase in prevalence. Sensitivity analysis identified that being a drug user was a good parameter that should be targeted for reproduction number (R_0) since to prevent drug use was better than curing it. They also recommended that, increasing prevention modalities should be done frequently other than emphasizing on relying on statistics of those individuals registered on treatment.

Chersich et al., (2007), in a paper on "Heavy Episodic Drinking among Kenyan Female sex workers in Mombasa" adduced that, about a third ($1/3$) of sex workers were HIV/AIDS infected. The study further revealed temporal linkages between use of alcohol and unsafe

sex. These two links might have been as a result of influence of alcohol on their correct use, negotiation on whether to use a condom and their incorrect use.

Ma et al., (2015) studied a lively alcohol intake model incorporating awareness and time delay, in which they desired to understand how this awareness was restraining the alcohol problems. They assumed the susceptible inhabitants avoided being in contact with each other because awareness programs execution resulted minimal drinking. The researchers argued that most of the alcoholism studies were Ordinary Differential Equation-oriented and did not incorporate the acts of time delay. In comparison to previous research, an integral novelty of their model was on introduction of delay in describing the time needed for an individual to become infectious. They discovered that embracing these programs was the main measure in controlling the alcohol problems by raising the value of time delay though bifurcation might appear.

Blower et al.,(1991)developed a design based on data to evaluate the effects of gender, injecting drug users and perinatal transmission. Though this study had thirty-four non-linear Ordinary Differential Equations, they analyzed and clarified the link between these modes of transmission and also provided great insights into the HIV/AIDS outbreak in New York City. The confidence intervals on the forecast estimates of accumulated estimates in the future of HIV/AIDS cases were broad. However, only a couple of variables are vital in contributing to the forecasting suggesting that to reduce estimation uncertainties in the biological-behavioral transmission parameters will probably have a much bearing on elevating the forecasting of adult HIV/AIDS instances than estimating sub-group sizes.

Mukandavire et al.,(2009) devised a compartmental design on the transmission dynamics of HIV/AIDS and malaria in a given community and rigorously evaluated it. The model considered the epidemiological synergy between malaria and sexually transmitted diseases. The study consisted of twelve non-linear Ordinary Differential Equations and they examined three components i.e malaria sub-model,HIV/AIDS sub-model and Malaria-HIV/AIDS sub-model. The results of the full HIV-malaria model revealed that the two infections co-existed so long as the reproduction number of each exceeded one another irrespective of their number sizes, as well as the number of new cases of malaria at steady state appears to always exceed that of HIV/AIDS. They also recommended for more research that considers the possible repercussions of HIV-Malaria co-infection in spread of HIV/AIDS

Thomas and Lungu., (2010) formulated a gender-based model on understanding these sexes, with varying heavy use of alcohol tendencies give rise to the HIV/AIDS spread differently. They used a system of twelve non-linear Ordinary Differential Equations. The duo concluded that binge drinking was a major force for HIV/AIDS among heavy drinking infected people.

P. Small et al., (1993) in their analysis on exogenous re-infection and drug resistance among the HIV infected people, concluded that immunity to anti-TB drugs could result not just in the virus that gave rise to that the original infection, but also in a new breed that could arise due to re-infection using a nother breed of M.TB which is resistant to drugs. Even Though the analysis was completed in the USA, the results are authentic worldwide (Barberis et al, .2017),

3 Model Formulation and Analysis

3.1 Model Formulation

We design a model which entails use of drugs in the population in aiding transmission of HIV/AIDS. We also carry out estimation of parameters and threshold values that will assist in describing the disease transmission dynamics and prediction of future trends and will help in suggesting how use of illicit drugs can be reduced to minimize HIV/AIDS transmission.

The population is divided into seven compartments. These compartments consist of susceptibles (S), infected (I) and individuals under treatments (T). Further we have susceptible individuals (S), individuals with drugs and substance use habits only (I_D) and individuals infected with HIV/AIDS only (I_H). Similarly we have dually infected individuals with HIV/AIDS and also drug users (I_{HD}) in addition we have HIV/AIDS positive individuals under treatment (T_H) and Drug users under treatment (T_D). Finally there are dually infected individuals (both with HIV/AIDS and on drugs) under treatment (T_{HD}). It's assumed that AIDS patients are left out because they are not sexually active due to their health status. Therefore, the expression for the population at anytime (t) is

$$N(t) = S + I_H + I_D + I_{HD} + T_H + T_D + T_{HD}$$

The assumption here is that susceptible are recruited at a constant rate Λ by natural birth. Those under treatment for drug use (T_D) relapse and become susceptible (at the rate γ_{2d}). Susceptible acquire HIV/AIDS status following contact with individuals with HIV/AIDS (at a rate β_1). This class may also increase by an assumption that youth under treatment for dual infection can become infected with HIV/AIDS after interacting effectively with HIV/AIDS positive youths (at the rate γ_{1d}). In addition, susceptibles acquire drug use condition majorly through effective interaction with other drug users. These can as a result of drinking friends, peer pressure, family members who also use drugs etc (at a rate β_2). Although typically there could be asymptomatic period, in this model we do not consider that and instead we assume that people gain infectiousness upon infection with drug abuse habits. Further natural death occurs in all human sub-populations (at a rate μ). The force of infection of HIV/AIDS infection is,

$$\lambda_H = \frac{\beta_1(I_H + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})}{N} \quad (1)$$

where β_1 is the contact rate for HIV/AIDS transmission. Further, the parameters $\pi_1 \geq 1$, π_2 and $\pi_3 \leq 1$ (i.e. $\pi_1 \geq \pi_2 \geq \pi_3$) account for the relative infectiousness of infected persons in the I_{HD} class, T_H and T_{HD} compartments respectively compared to those in the I_H class. That is, persons in the I_{HD} class are more infectious than those in the I_H group because of their higher viral load level, similarly, HIV/AIDS infected persons (T_H and T_{HD}) are less infectious than I_H class because being under therapy significantly reduces their viral load.

drug users acquire these habits at a rate;

$$\lambda_D = \frac{\beta_2(I_D + (1 - \pi_1)I_{HD} + \pi_4 T_D + (1 - \pi_3)T_{HD})}{N} \quad (2)$$

where β_2 determines the “influence” of I_{HD} , T_D and T_{HD} on S . $(1 - \pi_2)$, $(1 - \pi_3)$ and π_4 are modification parameters for $T_D T_{HD}$ which account for the increased likelihood of I_{HD}, I_D .

Individuals using illicit drugs get HIV/AIDS at a rate ω_2 . Those in I_D class move to I_{HD} on being HIV/AIDS positive at the rate ω_2 ($\omega_2 \geq 0$). These individuals can as well undergo treatment for drug use without acquiring HIV/AIDS at the rate ξ_2 . Furthermore, individuals infected with HIV/AIDS can acquire illicit drug use habits at a rate ω_1 . HIV/AIDS infected individuals can also undergo treatment therapy without necessarily being illicit drug users at the rate ξ_1 .

Finally, dually infected individuals can either receive treatment separately for each infection i.e. T_H for HIV/AIDS or T_D for illicit drug use at the rate ν_1 and ν_2 respectively or be treated for both conditions at the rate π . Moreover exit through death due to the severity of AIDS has been included hence AIDS class is left out because we assume that they are not sexually active to be pertinent in the infection process.

Individuals undergoing treatment singly for each infection may as well receive treatment for the subsequent infection at the rates α_1 and α_2 respectively. Further individuals in the I_H (HIV/AIDS infected) class, active I_D (those infected with drug abuse habits), I_{HD} (dual-infection-induced deaths at the rates δ_h, δ_d and δ_{hd} respectively).

3.2 Model equations

$$\left\{ \begin{array}{l}
 \frac{dS}{dt} = \Lambda + \gamma_{2d}T_D - \lambda_H S I_H - \lambda_D S I_D - \mu S \\
 \frac{dI_H}{dt} = \lambda_H S I_H + \gamma_{1d}T_{HD} - (\mu + \delta_h + \xi_1 + \omega_1)I_H \\
 \frac{dI_D}{dt} = \lambda_D S I_D - (\omega_2 + \xi_2 + \mu + \delta_d)I_D \\
 \frac{dI_{HD}}{dt} = \omega_1 I_H + \omega_2 I_D - (\nu_1 + \nu_2 + \mu + \delta_{hd})I_{HD} \\
 \frac{dT_H}{dt} = \nu_1 I_{HD} + \xi_1 I_H - (\alpha_1 + \mu + \delta_h)T_H \\
 \frac{dT_D}{dt} = \nu_2 I_{HD} + \xi_2 I_D - (\alpha_2 + \mu + \delta_d + \gamma_{2d})T_D \\
 \frac{dT_{HD}}{dt} = \alpha_1 T_H + \alpha_2 T_D - (\gamma_{1d} + \delta_{hd} + \mu)T_{HD}
 \end{array} \right. \quad (3)$$

And with the initial conditions as;

$$\begin{aligned}
 & S(0), I_H(0), I_D(0), I_{HD}(0), T_H(0), T_D(0), T_{HD}(0) \\
 & = (S)_o, (I_H)_o, (I_D)_o, (I_{HD})_o, (T_H)_o, (T_D)_o, (T_{HD})_o
 \end{aligned}$$




Figure 1(a). flow of individuals into different compartments

Description of variables and parameter used in the model

VARIABLE	DESCRIPTION
S	Susceptible population
I_H	HIV/AIDS Infected individuals
I_D	Infected Drug users
I_{HD}	Infectives with HIV/AIDS and use Drug
T_H	Individuals with HIV/AIDS under treatment
T_D	Drug users under treatment
T_{HD}	HIV/AIDS and Drug users under treatment

Table 1. Description of model variables

PARAMETER	DESCRIPTION
Λ	Recruitment rate for individuals by age
β_1	HIV/AIDS transmission rate
β_2	Drugs transmission rate
λ_H	Force of infection for HIV/AIDS
λ_D	Force of infection for drug abuse
ω_1	Rate at which HIV infected individuals become dually infected
ω_2	Rate at which drug users become dually infected
ν_1	Per capita treatment rate for HIV/AIDS
ν_2	Per capita treatment rate for Drug use
α_1	Rate at which T_H individuals receive treatment for dual infection
α_2	Rate at which T_D individuals receive for dual dual infection
ξ_1	Rate at which HIV/AIDS infected receive treatment for HIV/AIDS
ξ_2	Rate at which infected drug users receive treatment for Drug use
γ_{1d}	Rate at which dually infected on treatment quit
γ_{2d}	Relapse rate for drug abusers
μ	Natural death rate
δ_d	Drug abuse induced death rate
δ_h	HIV/AIDS induced death rate
δ_{hd}	Death rate due to dual disease infection

Table 2. Description of model parameters

3.3 Model Analysis

3.3.1 Positivity of solutions

Theorem 3.3.1. *Given $(S(0), I_H(0), I_D(0), I_{HD}(0), T_H(0), T_D(0), T_{HD}(0))$, the set*

$$\{S(t), I_D(t), I_H(t), I_{TD}(t), T_H(t), T_D(t), T_{HD}(t)\}$$

of model(3) is positively invariant for all $t \geq 0$.

Proof

The parameters here are non-negative and hence the system of equations in the model are well posed i.e For initial values $(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})$ in R_+^7 , the solutions exist, are unique and remain in the region for all $t \geq 0$.

when there is no infection, the total population is given by $\dot{N} = \Lambda - \mu N$. Here, $N(t)$ approaches a carrying capacity $\frac{\Lambda}{\mu}$ for any non-zero initial population size. we set

$$\lambda_H = \frac{\beta_1(I_H + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})}{N}$$

and

$$\lambda_D = \frac{\beta_2(I_D + (1 - \pi_1)I_{HD} + \pi_4 T_D + (1 - \pi_3)T_{HD})}{N}$$

such that the equations of model (3) take the form

$$\left\{ \begin{array}{l} \dot{S} = \Lambda + \gamma_{2d}T_D - \frac{\beta_1(I_H + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})}{N} S I_H - \\ \quad \frac{\beta_2(I_D + (1 - \pi_1)I_{HD} + \pi_4 T_D + (1 - \pi_3)T_{HD})}{N} S I_D - \mu S \\ \dot{I}_H = \frac{\beta_1(I_H + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})}{N} S I_H + \gamma_{1d}T_{HD} - \\ \quad (\mu + \delta_h + \xi_1 + \omega_1)I_H \\ \dot{I}_D = \frac{\beta_2(I_D + (1 - \pi_1)I_{HD} + \pi_4 T_D + (1 - \pi_3)T_{HD})}{N} S I_D \\ \quad - (\omega_2 + \xi_2 + \mu + \delta_d)I_D \\ \dot{I}_{HD} = \omega_1 I_H + \omega_2 I_D - (\nu_1 + \nu_2 + \mu + \delta_{hd})I_{HD} \\ \dot{T}_H = \nu_1 I_{HD} + \xi_1 I_H - (\alpha_1 + \mu + \delta_h)T_H \\ \dot{T}_D = \nu_2 I_{HD} + \xi_2 I_D - (\alpha_2 + \mu + \delta_d + \gamma_{2d})T_D \\ \dot{T}_{HD} = \alpha_1 T_H + \alpha_2 T_D - (\gamma_{1d} + \delta_{hd} + \mu)T_{HD} \end{array} \right. \quad (4)$$

The feasible region is

$$\Gamma = \{(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD}) \in \mathfrak{R}_+^7 : S \leq N, 0 \leq I_H \leq N, 0 \leq I_D \leq N, \\ 0 \leq I_{HD} \leq N, 0 \leq T_H \leq N, 0 \leq T_D \leq N, 0 \leq T_{HD} \leq N, N \geq 0\}$$

where \mathfrak{R}_+^7 denotes its non-negative cone including its lower dimensional forces. Clearly, Γ is positively invariant with respect to model (3) and we denote the boundary of Γ by $\partial\Gamma$ and its interior by $\dot{\Gamma}$

3.3.2 Boundedness

Theorem 3.3.2. *The model (1) solutions are uniformly bounded in a set $L = \{S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD}\} \in \mathfrak{R}_+^7; (N(0) \leq N(t) \leq \frac{\Lambda}{\mu})$*

$$\frac{dN}{dt} \leq \frac{dS}{dt} + \frac{dI_H}{dt} + \frac{dI_D}{dt} + \frac{dI_{HD}}{dt} + \frac{dT_H}{dT_D} + \frac{dT_D}{dt} + \frac{dT_{HD}}{dt} \quad (5)$$

$$\frac{dN}{dt} \leq \Lambda - \mu N - (\delta_h + \delta_d + \delta_{hd}) \quad (6)$$

When there is no infection in the population, there is no death due to the infection and hence $\delta_h = \delta_d = \delta_{hd} = 0$.

therefore, the RHS of (6) reduces to

$$\frac{dN}{dt} = \Lambda - \mu N \quad \text{and solving for } N, \quad (7)$$

$$\Rightarrow dN = (\Lambda - \mu N) dt \quad (8)$$

or

$$\frac{dN}{\Lambda - \mu N} = dt \quad (9)$$

by separation of variables.

Integrating both sides of (9) we get

$$\int \frac{dN}{\Lambda - \mu N} \leq \int dt \quad (10)$$

$$\Rightarrow -\frac{1}{\mu} \ln |\Lambda - \mu N| \leq t + C_1 \quad (11)$$

or

$$\ln |\wedge - \mu N| \leq -\mu t + C_2, \text{ where } C_2 = -\mu C_1 \quad (12)$$

taking exponential on both sides of (12) we get

$$e^{\ln |\wedge - \mu N|} \leq e^{C_2} \cdot e^{-\mu t} \quad (13)$$

or

$$\wedge - \mu N \leq C e^{-\mu t} \quad (14)$$

$$\Rightarrow N \leq \frac{\wedge - C e^{-\mu t}}{\mu} \quad (15)$$

$$N(t) \leq \frac{\wedge - C e^{-\mu t}}{\mu} \quad (16)$$

as $t \rightarrow \infty$,

$$N(t) \leq \frac{\wedge}{\mu} \quad (17)$$

hence the total population is bounded and is in the feasible

$$N(0) \leq N(t) \leq \frac{\wedge}{\mu}.$$

Therefore,

$$L = \{(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD}) \in \mathbb{R}_+^7 \mid 0 \leq S + I_H + I_D + I_{HD} + T_H + T_D + T_{HD} \leq \frac{\wedge}{\mu}\}$$

and it is clear that L is positively invariant with respect to model (3). We denote the boundary and the interior of L by ∂L and $\overset{\circ}{L}$ respectively.

3.3.3 Existence and Stability of Equilibria

$$A_4 = \alpha_1 + \delta_h + \mu,$$

$$A_5 = \alpha_2 + \delta_d + \gamma_{2d} + \mu,$$

$$A_6 = \gamma_{1d} + \delta_{hd} + \mu$$

We decompose the RHS of the infected subsystem into two parts \mathcal{F} and \mathcal{V}

$$\text{where } \mathcal{F} = \left[\frac{\partial F_i(x_o)}{\partial x_j} \right]$$

and

$$\mathcal{V} = \left[\frac{\partial V_i(x_o)}{\partial x_j} \right]$$

the matrix of the new infection

$$\mathcal{F} = \begin{bmatrix} \lambda_{HS} \\ \lambda_{DS} \\ o \\ o \\ o \\ o \end{bmatrix}$$

$$\mathcal{F} = \begin{bmatrix} \frac{S}{N}(\beta_1(I_D + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})) \\ \frac{S}{N}(\beta_2(I_D + (1 - \pi_1)I_{HD} + \pi_4 T_D + (1 - \pi_3)T_{HD})) \\ o \\ o \\ o \\ o \end{bmatrix}$$

We obtain the Jacobian of \mathcal{F} with respect to $I_H, I_D, I_{HD}, T_H, T_D, T_{HD}$ and at Disease free equilibrium,

$$F = \begin{bmatrix} \beta_1 & 0 & \beta_1\pi_1 & \beta_1\pi_2 & 0 & \beta_1\pi_3 \\ 0 & \beta_2 & \beta_2(1-\pi_1) & 0 & \beta_2(1-\pi_4) & \beta_2(1-\pi_3) \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \end{bmatrix}$$

and transfer of infection

$$\mathcal{V} = \begin{bmatrix} -\gamma_{1d}T_{HD} + A_1I_H \\ A_2I_D \\ -\omega_1I_H - \omega_2I_D + A_3I_{HD} \\ -\nu_1I_{HD} - \xi_1I_H + A_4T_H \\ -\nu_2I_{HD} - \xi_2I_D + A_5T_D \\ -\alpha_1T_H - \alpha_2T_D + A_6T_{HD} \end{bmatrix}$$

We obtain the Jacobian of \mathcal{V} with respect to $I_H, I_D, I_{HD}, T_H, T_D, T_{HD}$ and at Disease free equilibrium,

$$V = \begin{bmatrix} A_1 & 0 & 0 & 0 & 0 & -\gamma_{1d} \\ 0 & A_2 & 0 & 0 & 0 & 0 \\ -\omega_1 & -\omega_2 & A_3 & 0 & 0 & 0 \\ -\xi_1 & 0 & -\nu_1 & A_4 & 0 & 0 \\ 0 & -\xi_2 & -\nu_2 & 0 & A_5 & 0 \\ 0 & 0 & 0 & -\alpha_1 & -\alpha_2 & A_6 \end{bmatrix}$$

Where

$$\begin{aligned}
A_1 &= \mu + \delta_h + \xi_1 + \omega_1 \\
A_2 &= \nu_1 + \nu_2 + \mu + \delta_{hd} \\
A_3 &= \alpha_1 + \mu + \delta_h \\
A_4 &= \gamma_{1d} + \delta_{hd} + \mu \\
A_5 &= \omega_1 + \omega_2 + \mu + \delta_d \\
A_6 &= \alpha_2 + \mu + \delta_d + \gamma_{2d}
\end{aligned}$$

$$FV^{-1} = \begin{bmatrix} \underline{y_1} & \underline{y_3} & \underline{y_5} & \underline{y_7} & \underline{y_9} & \underline{y_{11}} \\ \underline{y_2} & \underline{y_4} & \underline{y_6} & \underline{y_8} & \underline{y_{10}} & \underline{y_{12}} \\ \underline{y_{13}} & \underline{y_{15}} & \underline{y_{17}} & \underline{y_{19}} & \underline{y_{21}} & \underline{y_{23}} \\ \underline{y_{14}} & \underline{y_{16}} & \underline{y_{18}} & \underline{y_{20}} & \underline{y_{22}} & \underline{y_{24}} \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 \end{bmatrix}$$

where

$$\frac{y_1}{y_2} = \frac{\beta_1(A_3A_5(A_4A_6x_1 + A_6\pi_1 + \pi_3\alpha_1)\xi_1)}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1)}$$

$$\frac{y_3}{y_4} = \frac{(\beta_1(\alpha_2\xi_2(A_1A_3A_4\pi_3(A_4(A_1\pi + \gamma_{1d}(A_3(A_4 + \pi_1\xi_1)))))))}{(A_2A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1))}$$

$$\frac{y_5}{y_6} = \frac{\beta_1(A_1(A_5(A_6\pi_1 + \pi_3\alpha_1)\nu_1 + A_4(A_5A_6\pi_1 + \pi_3\alpha_2\nu_2)))}{A_3A_5(A_1A_4A_6 - \alpha_1d) - \gamma_{1d}(A_5\alpha_1\nu_1 - A_4\alpha_2\nu_2)\omega_1}$$

$$\frac{y_7}{y_8} = \frac{\beta_1(A_3A_5(A_1(A_6\pi_1 + \pi_3\alpha_1) + \alpha_1\gamma_{1d}) + \pi_1\gamma_{1d}(A_5\alpha_1 - \alpha_2\nu_2)\omega_1)}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1)}$$

$$\frac{y_9}{y_{10}} = \frac{\alpha_2\beta_1(A_1A_3A_4\pi_3 + \gamma_{1d}(A_3(A_4 + \pi_1\xi_1) + \pi_1(A_4 + \nu_1)\omega_1))}{A_3A_5(-A_1A_4A_6 + \alpha_1\gamma_{1d}\xi_1)}$$

$$\frac{y_{11}}{y_{12}} = \frac{A_5\beta_1(A_1A_3A_4\pi - 3 + \gamma_{1d}(A_3(A_4 + \pi_1\xi_1) + \pi_1(A_4 + \nu_1)\omega_1))}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1)}$$

$$\frac{y_{13}}{y_{14}} = \frac{\beta_2(A_2A_3(-1 + \pi_3)\alpha_1\xi_1 + (A_5(-1 + \pi_3)\alpha_1\nu_1 + A_4(A_5A_6(-1 + \pi_1)))}{A_3A_5(-A_1A_4A_6 + \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

$$\frac{y_{15}}{y_{16}} = \frac{(\beta_2(A_1(A_3A_4(A_5A_6 + (A_6 - A_6\pi_4 + \alpha_2 - \pi_3\alpha_2))\xi_2))}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

$$\frac{y_{17}}{y_{18}} = \{-\beta_2(A_1(A_5(-1 + \pi_3)\alpha_1\nu_1 + A_4(A_5A_6(-1 + \pi_1) + (A - 6(-1 + \pi_4) + (-1 + \pi_3)\alpha_2)\nu_2)))\} / \{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\}$$

$$\frac{y_{19}}{y_{20}} = \frac{\alpha_1\beta_2(A_1A_3A_5(-1 + \pi_3) + \gamma_{1d}(A_5(-1 + \pi_1) + (-1 + \pi_4)\pi_2)\omega_1)}{A_2A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

$$\frac{y_{21}}{y_{22}} = \frac{\beta_2(A_1A_3A_4(-A_6(-1 + \pi_4) - (-1 + \pi_3)\alpha_2))}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

$$\frac{y_{23}}{y_{24}} = \frac{\beta_2A_4(A_1A_3A_5(-1 + \pi_3) + \gamma_{1d}(A_5(-1 + \pi_1) + (-1 + \pi_4)\nu_2)\omega_1)}{A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

Eigenvalues of FV^{-1} are

$$\lambda_1 = 0$$

$$\lambda_2 = 0$$

$$\lambda_3 = 0$$

$$\lambda_4 = 0$$

$$\lambda_5 = \frac{-\sqrt{A_1^2\xi_1^2 - 2A_1A_2\xi_2\omega_1 + A_2^2\omega_1^2 + 4A_1A_2\nu_1\omega_2 + A_1\xi_1 + A_2\omega_1}}{2A_1A_2A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

$$\lambda_6 = \frac{+\sqrt{A_1^2\xi_1^2 - 2A_1A_2\xi_2\omega_1 + A_2^2\omega_1^2 + 4A_1A_2\nu_1\omega_2 + A_1\xi_1 + A_2\omega_1}}{2A_1A_2A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

The dominant eigenvalue is λ_6 which is the basic reproduction number and hence $\mathcal{R}_{HD} =$

$$\frac{+\sqrt{A_1^2\xi_1^2 - 2A_1A_2\xi_2\omega_1 + A_2^2\omega_1^2 + 4A_1A_2\nu_1\omega_2 + A_1\xi_1 + A_2\omega_1}}{2A_1A_2A_3A_5(A_1A_4A_6 - \alpha_1\gamma_{1d}\xi_1) - \gamma_{1d}(A_5\alpha_1\nu_1 + A_4\alpha_2\nu_2)\omega_1}$$

3.3.6 Local stability of the E_{HD}

We establish E_{HD} point i.e when there is no infection, the system has a constant solution, $E_{HD} = (\frac{\wedge N}{\mu}, 0, 0, 0, 0, 0)$.

Theorem 3.3.3. *The infection-drug free equilibrium, E_{HD} is locally asymptotically stable if $\mathcal{R}_{HD} < 0$.*

proof

To establish this stability, we compute the Jacobian of the system at E_{HD} . The stability of E_{HD} is determined by the signs of the eigenvalues of the Jacobian matrix.

$$J(E_o) = \begin{bmatrix} -\mu & 0 & 0 & 0 & 0 & \gamma_{2d} & 0 \\ 0 & -A_1 & 0 & 0 & 0 & 0 & \gamma_{1d} \\ 0 & 0 & -A_2 & 0 & 0 & 0 & 0 \\ 0 & \omega_1 & \omega_2 & -A_3 & 0 & 0 & 0 \\ 0 & \xi_1 & 0 & \nu_1 & -A_4 & 0 & 0 \\ 0 & 0 & \xi_2 & \nu_2 & 0 & -A_5 & 0 \\ 0 & 0 & 0 & 0 & \alpha_1 & \alpha_2 & -A_6 \end{bmatrix}$$

$|J_{E_o} - XI| = 0$ as follows

$$J = \begin{vmatrix} -\mu - X & 0 & 0 & 0 & 0 & \gamma_{2d} & 0 \\ 0 & A_1 - X & 0 & 0 & 0 & 0 & \gamma_{1d} \\ 0 & 0 & A_2 - X & 0 & 0 & 0 & 0 \\ 0 & \omega_1 & \omega_2 & A_3 - X & 0 & 0 & 0 \\ 0 & \xi_1 & 0 & \nu_2 & A_4 - X & 0 & 0 \\ 0 & 0 & \xi_2 & \nu_2 & 0 & A_5 - X & 0 \\ 0 & 0 & 0 & 0 & \alpha_1 & \alpha_2 & A_6 - X \end{vmatrix}$$

The characteristic polynomial of J_{E_o} is

$$(X - \mu)(-X - A_2)[(X^2 + A_1X + A_3X + A_1A_3)(-X - A_5)(-X - A_6) + \gamma_{1d}(-(-X - A_5)) \\ \alpha_1(X\xi_1 + A_3\xi_1 + \nu_1\omega_1) + \alpha_2(X\mu_2\omega_1 + A_4\nu_2\omega_1)]$$

Notice that from column (1), $(-\mu - X)$ can be factored straight away, and also $X_2 = -A_2$. The other four remaining eigenvalues are obtained by solving the reduced polynomial below:

$$[(X^2 + A_1X + A_3X + A_1A_3)(-X - A_5)(-X - A_6) + \gamma_{1d}(-(-X - A_5))] \quad (24)$$

and using the Routh-Hurwitz criterion, the other roots are obtained

Lemma 3.3.4. *The infection-drug free equilibrium point (E_{HD}) is stable iff all the elements appearing in column one are all positive otherwise unstable (Routh's.,1874).*

Proof

By constructing the Routh-Hurwitz array for equation (24) and examining the elements of the column one, being negative, the system is considered unstable.

3.3.7 Global stability analysis of E_{HD}

The Global stability of infection-drug free equilibrium point (E_{HD}) is investigated using the Lyapunov function for some positive parameters, p_i , where $i = 1, 2, 3, 4, 5$ and 6.

$$\begin{aligned}
 V(S, I_H, I_D, I_{HD}, T_H, T_H, T_{HD}) &= \left(S - S^o - S^o \ln \left(\frac{S}{S^o} \right) \right) \\
 &+ p_1 \left(I_H - I_H^o - I_H^o \ln \left(\frac{I_H}{I_H^o} \right) \right) + p_2 \left(I_D - I_D^o - I_D^o \ln \left(\frac{I_D}{I_D^o} \right) \right) \\
 &+ p_3 \left(I_{HD} - I_{HD}^o - I_{HD}^o \ln \left(\frac{I_{HD}}{I_{HD}^o} \right) \right) + p_4 \left(T_H - T_H^o - T_H^o \ln \left(\frac{T_H}{T_H^o} \right) \right) \\
 &\quad + P_5 T_D + P_6 T_{HD}. \tag{25}
 \end{aligned}$$

satisfying the following conditions

1. $V(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_H^o, T_{HD}^o) = 0$
2. $V(S, I_H, I_D, I_{HD}, T_H, T_H, T_{HD}) > 0$
3. $\frac{dL}{dt}(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_H^o, T_{HD}^o) = 0$
4. $\frac{dl}{dt}(S, I_H, I_D, I_{HD}, T_H, T_H, T_{HD}) < 0$

Proof

Condition (1)

$$V(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_D^o, T_{HD}^o) = \left(S^o - S^o - S^o \ln \left(\frac{S^o}{S^o} \right) \right)$$

$$\begin{aligned}
& +p_1 \left(I_H^o - I_H^o - I_H^o \ln \left(\frac{I_H^o}{I_H^o} \right) \right) + p_2 \left(I_D^o - I_D^o - I_H^o \ln \left(\frac{I_D^o}{I_D^o} \right) \right) \\
& +p_3 \left(I_{HD}^o - I_{HD}^o - I_{HD}^o \ln \left(\frac{I_{HD}^o}{I_{HD}^o} \right) \right) + p_4 \left(T_H^o - T_H^o - T_H^o \ln \left(\frac{T_H^o}{T_H^o} \right) \right) \\
& +P_5 T_D^o + P_6 T_{HD}^o = 0
\end{aligned}$$

and hence the proof

Condition (2)

the derivative of V with respect to t is,

$$\begin{aligned}
\frac{dV(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_D^o, T_{HD}^o)}{dt} &= \left(1 - \frac{S^o}{S^o} \right) \frac{dS^o}{dt} + p_1 \left(1 - \frac{I_H^o}{I_H^o} \right) \frac{dI_H^o}{dt} \\
&+ p_2 \left(1 - \frac{I_D^o}{I_D^o} \right) \frac{dI_D^o}{dt} + p_3 \left(1 - \frac{I_{HD}^o}{I_{HD}^o} \right) \frac{dI_{HD}^o}{den} \\
&+ p_4 \left(1 - \frac{T_H^o}{T_H^o} \right) \frac{dT_H^o}{dt} + P_5 \frac{dT_D^o}{dt} + P_6 \frac{dT_{HD}^o}{dt}.
\end{aligned}$$

since $I_H^o = I_D^o = I_{HD}^o = T_H^o = T_D^o = T_{HD}^o = 0$ and $S^o = \frac{\Lambda}{\mu}$, the time derivative of the Lyapunov function V at infection-drug free equilibrium point reduces to

$$\frac{dV(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_D^o, T_{HD}^o)}{dt} = \left(1 - \frac{S^o}{S^o} \right) \frac{dS^o}{dt}$$

and since $1 - \frac{S^o}{S^o} = 0$, then $\frac{dS^o}{dt} = 0$

Hence

$$\frac{dV(S^o, I_H^o, I_D^o, I_{HD}^o, T_H^o, T_D^o, T_{HD}^o)}{dt} = 0$$

Similarly,

$$\frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} = \left(1 - \frac{S^o}{S} \right) \frac{dS}{dt} + p_1 \left(1 - \frac{I_H^o}{I_H} \right) \frac{dI_H}{dt}$$

$$+p_2 \left(1 - \frac{I_D^o}{I_D}\right) \frac{dI_D}{dt} + p_3 \left(1 - \frac{I_{HD}^o}{I_{HD}}\right) \frac{dI_{HD}}{dt} + p_4 \left(1 - \frac{T_H^o}{T_H}\right) \frac{dT_H}{dt} \\ + P_5 \frac{dT_D}{dt} + P_6 \frac{dT_{HD}}{dt}.$$

replacing for

$\frac{dS}{dt}$, $\frac{dI_H}{dt}$, $\frac{dI_D}{dt}$, $\frac{dI_{HD}}{dt}$, $\frac{dT_D}{dt}$, $\frac{dT_H}{dt}$ and $\frac{dT_{HD}}{dt}$, we get

$$\frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} = \left(1 - \frac{S^o}{S}\right) (\wedge + \gamma_{2d}T_D - \lambda_H S I_H - \lambda_D S I_D - \mu S) \\ + p_1 \left(1 - \frac{I_H^o}{I_H}\right) (\lambda_H S I_H + \gamma_{1d}T_{HD} - A_1 I_H) \\ + p_2 \left(1 - \frac{I_D^o}{I_D}\right) (\lambda_D S I_D - A_2 I_D) \\ + p_3 \left(1 - \frac{I_{HD}^o}{I_{HD}}\right) (\omega_1 I_H + \omega_2 I_D - A_3 I_{HD}) \\ + p_4 \left(1 - \frac{T_H^o}{T_H}\right) (\nu_1 I_{HD} + \xi_1 I_H - A_4 T_H) \\ + P_5 (\nu_2 I_{HD} + \xi_2 I_D - A_5 T_D) \\ + P_6 (\alpha_1 T_H + \alpha_2 T_D - A_6 T_{HD})$$

expanding and simplifying yields,

$$\frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} = S^o \mu S - S^o \wedge + S \wedge - S^2 \mu + (-S^o + S) T_D \gamma_{2d} \\ + (S^o - S) S I_D \lambda_D + S^o S I_H \lambda_H - S^2 I_H \lambda_H \\ + S P_1 I_H \lambda_H + P_1 T_{HD} \gamma_{1d} - \alpha_1 P_1 I_H - S I_H^o P_1 \lambda_H \\ - \frac{P_1 T_{HD} I_H^o \gamma_{1d}}{I_H} + P_1 A_1 I_H^o + I_D^o A_2 P_2 - I_D A_2 P_2 \\ - I_D^o S P_2 \lambda_D + I_D S P_2 \lambda_D - I_{HD} A_3 P_3 + I_{HD}^o A_3 P_3 \\ + P_3 I_H \omega_1 - I_{HD} \frac{P_3 I_H \omega_1}{I_{HD}} + I_D P_3 \omega_2 - \frac{I_{HD}^o I_D P_3 \omega_2}{I_{HD}} \\ + T_H^o A_4 P_4 - A_4 P_4 T_H + I_{HD} P_4 \nu_1 - \frac{T_H^o I_{HD} P_4 \nu_1}{T_H} \\ + P_4 I_H \xi_1 - \frac{T_H^o P_4 I_H \xi_1}{T_H} + P_5 \nu_2 I_{HD} + P_5 \xi_2 I_D \\ - P_5 A_5 T_D + P_6 \alpha_1 T_H + P_6 \alpha_2 T_D - P_6 A_6 T_{HD}$$

At infecton-drug free equilibrium point,

$$I_H^o = I_D^o = I_{HD}^o = T_H^o = T_D^o = T_{HD}^o = 0$$

reducing the equation to

$$\begin{aligned} \frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} = & \frac{S^o \mu S - S^o \wedge + S \wedge - S^2 \mu + (-S^o + S) T_D \gamma_{2d} + (S^o - S) S I_D \lambda_D + S^o S I_H \lambda_H - S^2 I_H \lambda_H}{S} \\ & + S P_1 I_H \lambda_H - A_4 P_4 T_H + I_{HD} P_4 \nu_1 + P_4 I_H \xi_1 + P_5 \nu_2 I_{HD} + P_5 \xi_2 I_D + I_D - P_5 A_5 T_D \\ & + P_6 \alpha_1 T_H + P_6 \alpha_2 T_D - P_6 A_6 T_{HD} \\ = & 2 \wedge - \frac{\wedge^2}{\mu S} + \frac{(S - \frac{\wedge}{\mu}) T_D \gamma_{2d}}{S} + (\frac{\wedge}{\mu} - S) I_D \lambda_D + \frac{\wedge}{\mu} I_H \lambda_D + S I_H \lambda_H + S P_1 I_H \lambda_H \\ & + P_1 T_{HD} \gamma_{1d} - A_1 P_1 I_H - I_D A_2 P_2 + I_D S P_2 \lambda_D - I_H A_3 P_3 + P_3 I_H \omega_1 + I_D P_3 \omega_2 - A_4 P_4 T_H \\ & + I_{HD} P_4 \nu_1 + P_4 I_H \xi_1 + P_5 \nu_2 I_{HD} + P_5 \xi_2 I_D - P_5 A_5 T_D + P_6 \alpha_1 T_H + P_6 \alpha_2 T_D - P_6 A_6 T_{HD} \end{aligned}$$

Grouping the non-linear terms on the RHS

$$\begin{aligned} \frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} = & 2 \wedge - \frac{\wedge^2}{\mu S} - S \mu + (P_4 - 1) S I_H \lambda_H \\ & + (P_2 - 1) S I_D \lambda_D + (P_3 \omega_1 + P_4 \xi_1 - A_1 P_1) I_H \\ & + (P_3 \omega_2 + P_5 \xi_2 - A_2 P_2) I_D \\ & + (P_4 \nu_1 + P_5 \nu_2 - A_3 P_3) I_{HD} + \\ & (P_6 \alpha_1 - A_4 P_4) T_H \\ & + (P_6 \alpha_2 + \gamma_{2d} - \frac{\wedge}{\mu S} \gamma_{2d} - P_5 A_5) T_D \\ & + (P_1 \gamma_{1d} - P_6 A_6) T_{HD} + \frac{\wedge}{\mu} I_{HD} \lambda_H + \frac{\wedge}{\mu} I_D \lambda_D \end{aligned}$$

Equating the non-linear terms to zero we get,

$$\begin{aligned} P_1 = 1, \quad P_2 = 1, \quad P_3 = \frac{A_1}{\omega_1} - \frac{\gamma_{1d}}{\omega_1 A_4 A_6} \alpha_1 \xi_1, \quad P_4 = \frac{\gamma_{1d}}{A_4 A_6} \\ P_5 = \frac{A_2}{\xi_2} + \frac{\gamma_{1d}}{\omega_1 \xi_1 A_4 A_6} \alpha_1 \xi_1 - \frac{A_1}{\omega_1 \xi_2}, \quad P_6 = \frac{\gamma_{1d}}{A_6} \end{aligned}$$

Since

$$2 \wedge - \frac{\wedge^2}{\mu} S - S\mu < 0$$

thus ,

$$\frac{dV(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD})}{dt} < 0$$

hence the two conditions are satisfied for infection-free equilibrium point to be GAS

all parameters being non-positive, then $\dot{V} \leq 0$ for $R_{HD} < 1$

therefore, V is a Lyapunov function on L, and the largest compact invariant set in

$\{(S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD}) \in L : \dot{V} = 0\}$ is the singleton $\{E_{HD}\}$. Therefore, by LaSalle's Invariance Principle (LaSalle., 1976), every solution of model (1), with initial conditions in L, approaches E_{HD} as $t \rightarrow \infty$, whenever $R_o \leq 0$. This completes the proof.

3.3.8 Endemic Equilibrium Point, E^*

This is usually when the infection is present in the human population. It's obtained when atleast one of the infected components is not equal to zero. For model(1) they are given by

$$E^* = (S^*, I_H^*, I_D^*, I_{HD}^*, T_H^*, T_D^*, T_{HD}^*)$$

For E^* to exist,

$$S^* > 0, I_H^* > 0, I_D^* > 0, I_{HD}^* > 0, T_H^* > 0, T_D^* > 0, T_{HD}^* > 0$$

We set the RHS of system of differential equations (1) to zero and obtain

$$\wedge + \gamma_{2d} T_D^* - \lambda_H S^* I_H^* - \lambda_D S^* I_D^* - \mu S^* = 0 \quad (26)$$

$$\lambda_H S^* I_H^* + \gamma_{1d} T_{HD}^* - A_1 I_H^* = 0 \quad (27)$$

$$\lambda_D S^* I_D^* - A_2 I_D^* = 0 \quad (28)$$

$$\omega_1 I_H^* + \omega_2 I_D^* - A_3 I_{HD}^* = 0 \quad (29)$$

$$\nu_1 I_{HD}^* + \xi_1 I_H^* - A_4 T_H^* = 0 \quad (30)$$

$$\nu_2 I_{HD}^* + \xi_2 I_D^* - A_5 T_D^* = 0 \quad (31)$$

$$\alpha_1 T_H^* + \alpha_2 T_D^* - A_6 T_{HD}^* = 0 \quad (32)$$

solving for S^* , I_H^* , I_D^* , I_{HD}^* , T_H^* , T_D^* and T_{HD}^* and using Mathematica software we obtain

$$S^* = \frac{N A_2 A_5}{\beta_2 (A_5 + \pi_4 \xi_2)}$$

$$I_H^* = \frac{A_4(A_4 \wedge \beta_1 \xi_1 + \wedge \pi_2 \beta_1 \xi_1^2 - K_2)}{2\xi_1 K_4}$$

$$I_D^* = \frac{-A^2 \beta_1 \xi_1 \wedge + A_4 A_5 \beta_1 \xi_1 \wedge - A_4 \pi_2 \beta_1 \xi_1 \wedge + A_5 \pi_2 \beta_1 \xi_1 \wedge + K_3 + K_4 + \frac{A_5(-\gamma_{2d} + K_5)}{K_6}}{\xi_1}$$

$$I_{HD}^* = \frac{-A_4 \beta_1 \xi_1 \wedge + A_4 A_5 \beta_1 \xi_1^2 \wedge + A_5 \pi_2 \beta_1 \xi_1^2 + A_4 K_7 + A_5 K_8}{2A_1 A_4 \beta_1 \nu_1 (A_4 + \pi_2 \xi_1)}$$

$$T_H^* = \frac{A_4 \beta_1 \xi_1 \wedge + \pi_2 \beta_1 \xi_1^* K_9}{2K_{10}}$$

$$T_D^* = \frac{-\gamma_{2d} K_{11}}{2K_{12}}$$

$$T_{HD}^* = \frac{-\alpha_1 \left(\frac{A_4 \beta_1 \xi_1 \wedge + \pi_2 \beta_1 \xi_1^2 \wedge + K_{13} - \frac{\alpha_2(-\gamma_{2d} + K_{14})}{2K_{15}}}{K_{16}} \right)}{A_6}$$

where

$$K_1 = \sqrt{4N\mu A_1 \xi_1^2 (-A_1 A_4^2 \beta_1 - A_1 A_4 \pi_2 \beta_1 \xi_1) + (\wedge A_4 \beta_1 \xi_1 + \wedge \pi_2 \beta_1 \xi_1)^2}$$

$$K_2 = A_1 A_4^2 \beta_1 - A_1 A_4 \pi_2 \beta_1 \xi_1,$$

$$K_3 = A_4 \sqrt{\beta_1 \xi_1^2 (A_4 + \pi_2 \xi_1) (-4\mu A_1^2 A_4 + \wedge^2 A_4 \beta_1 + \wedge^2 \pi_2 \beta_1 \xi_1)}$$

$$K_4 = A_5 \sqrt{\beta_1 \xi_1^2 (A_4 + \pi_2 \xi_1) (-4N\mu A_1^2 A_4 + \wedge^2 A_4 \beta_1 + \wedge^2 \pi_2 \beta_1 \xi_1)}$$

$$K_5 = \sqrt{\gamma_{2d}^2 - 4 \left(\wedge \frac{N\mu A_2 A_5}{\beta_2 (A_5 + \pi_4 \xi_2)} \right) \left(\frac{-A_2 A_5^3}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)},$$

$$K_6 = 2 \left(-\frac{A_2 A_5^3}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)$$

$$K_7 = \sqrt{\beta_1 \xi_1^2 (A_4 + \pi_2 \xi_1) (-4N\mu A_1^2 A_4 + \wedge^2 A_4 \beta_1 + \wedge^2 A_4 \beta_1 + \wedge^2 \pi_2 \beta_1 \xi_1)}$$

$$K_8 = \sqrt{\beta_1 \xi_1^2 (A_4 + \pi_2 \xi_1) (-4N\mu A_1^2 A_4 + \wedge^2 A_4 \beta_1 + \wedge^2 \pi_2 \beta_1 \xi_1)}$$

$$K_9 = \sqrt{4N\mu \xi_1^2 A_1 (-A_1 A_4^2 \beta_1 - A_1 A_4 \pi_2 \beta_1 \xi_1 + (\wedge A_4 \beta_1 \xi_1 + \wedge \pi_2 \beta_1 \xi_1^2)^2)}$$

$$K_{10} = A_1 A_4^2 \beta_1 + A_1 A_4 \pi_2 \beta_1 \xi_1,$$

$$K_{11} = \left(\wedge \frac{N \mu A_2 A_5}{\beta_2 (A_5 + \pi_4 \xi_2)} \right) \left(\frac{A_2 A_5^3}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)$$

$$K_{12} = \left(-\frac{A_2 A_5^2}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)$$

$$K_{13} = \sqrt{4N\mu A_1 \xi_1^2 (-A_1 A_4 \beta_1 - A_1 A_4 \pi_2 \beta_1 \xi_1) + (\wedge A_4 \beta_1 \xi_1 + \wedge \pi_2 \beta_1 \xi_1^2)^2}$$

$$K_{14} = 2 \left(A_1 A_4^2 \beta_1 + A_1 A_4 \pi_2 \beta_1 \xi_1 \right),$$

$$K_{15} = 4 \left(\wedge \frac{N \mu A_2 A_5^3}{\beta_2 (A_5 + \pi_4 \xi_2)} \right) \left(\frac{-A_2 A_5}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)$$

$$K_{16} = \left(\frac{-A_2 A_5^3}{\xi_2^2 (A_5 + \pi_4 \xi_2)} - \frac{A_2 A_5^2 \pi_4}{\xi_2 (A_5 + \pi_4 \xi_2)} \right)$$

it is observed that the model has one endemic state and therefore a forward bifurcation exists.

3.3.9 Global stability of drug endemic equilibrium

Theorem 3.3.5. *If $R_o > 1$, then the infection-drug endemic equilibrium is globally asymptotically stable.*

Proof

By considering a Lyapunov logarithmic function defined by;

$$\begin{aligned}
L(S^*, I_H^*, I_D^*, I_{HD}^*, T_H^*, T_D^*, T_{HD}^*) &= \left(S - S^* - S^* \ln \left(\frac{S}{S^*} \right) \right) \\
&+ \left(I_H - I_H^* - I_H^* \ln \left(\frac{I_H}{I_H^*} \right) \right) \\
&+ \left(I_D - I_D^* - I_D^* \ln \left(\frac{I_D}{I_D^*} \right) \right) \\
&+ \left(I_{HD} - I_{HD}^* - I_{HD}^* \ln \left(\frac{I_{HD}}{I_{HD}^*} \right) \right) \\
&+ \left(T_H - T_H^* - T_H^* \ln \left(\frac{T_H}{T_H^*} \right) \right) \\
&+ \left(T_D - T_D^* - T_D^* \ln \left(\frac{T_D}{T_D^*} \right) \right) \\
&+ \left(T_{HD} - T_{HD}^* - T_{HD}^* \ln \left(\frac{T_{HD}}{T_{HD}^*} \right) \right)
\end{aligned}$$

computing the derivative of L along the solutions of the system of equations directly;

$$\begin{aligned}
\frac{dL}{dt} &= \left(1 - \frac{S}{S^*} \right) \frac{dS^*}{dt} + \left(1 - \frac{I_H}{I_H^*} \right) \frac{dI_H^*}{dt} + \left(1 - \frac{I_D}{I_D^*} \right) \frac{dI_D^*}{dt} \\
&+ \left(1 - \frac{I_{HD}}{I_{HD}^*} \right) \frac{dI_{HD}^*}{dt} + \left(1 - \frac{T_H}{T_H^*} \right) \frac{dT_H^*}{dt} \\
&+ \left(1 - \frac{T_D}{T_D^*} \right) \frac{dT_D^*}{dt} + \left(1 - \frac{T_{HD}}{T_{HD}^*} \right) \frac{dT_{HD}^*}{dt}
\end{aligned}$$

substituting for

$$\frac{dS^*}{dt}, \frac{dI_H^*}{dt}, \frac{dI_D^*}{dt}, \frac{dI_{HD}^*}{dt}, \frac{dT_H^*}{dt}, \frac{dT_D^*}{dt} \text{ and } \frac{dT_{HD}^*}{dt}$$

$$\begin{aligned}
\frac{dL}{dt} = & \left(1 - \frac{S}{S^*}\right) (\wedge + \gamma_{2d}T_D^* - \lambda_H S^* I_H^* - \lambda_D S^* I_D^* - \mu S^*) \\
& + \left(1 - \frac{I_H}{I_H^*}\right) (\lambda_H S^* I_H^* + \gamma_{1d}T_{HD}^* - A_1 I_H^*) \\
& + \left(1 - \frac{I_D}{I_D^*}\right) (\lambda_D S^* I_D^* - A_2 I_D^*) \\
& + \left(1 - \frac{I_{HD}}{I_{HD}^*}\right) (\omega_1 I_H^* + \omega_2 I_D^* - A_3 I_{HD}^*) \\
& + \left(1 - \frac{T_H}{T_H^*}\right) (\nu_1 I_{HD}^* + \xi_1 I_H^* - A_4 T_H^*) \\
& + \left(1 - \frac{T_D}{T_D^*}\right) (\nu_2 I_{HD}^* + \xi_2 I_D^* - A_5 T_D^*) \\
& + \left(1 - \frac{T_{HD}}{T_{HD}^*}\right) (\alpha_1 T_H^* + \alpha_2 T_D^* - A_6 T_{HD}^*)
\end{aligned}$$

Expanding and simplifying,

$$\begin{aligned}
\frac{dL}{dt} = & \wedge + \gamma_{2d}T_D^* - \lambda_H S^* I_H^* - \lambda_D S^* I_D^* - \mu S - \frac{S}{S^*} \wedge - \gamma_{2d}T_D^* \frac{S}{S^*} + \lambda_H I_H^* S \\
& + \lambda_D I_D^* S + \mu S + \lambda_H S^* I_H^* + \gamma_{1d}T_{HD}^* - A_1 I_H^* - \lambda_H S^* I_H \\
& - \gamma_{1d}T_{HD}^* \frac{I_H}{I_H^*} + A_1 I_H + \lambda_D S^* I_D^* - A_2 I_D^* - \lambda_D S^* I_D - A_2 I_D \\
& + \omega_1 I_H^* + \omega_2 I_D^* - A_3 I_{HD}^* - \omega_1 I_H^* \frac{I_{HD}}{I_{HD}^*} - \omega_2 I_D^* \frac{I_{HD}}{I_{HD}^*} + A_3 I_{HD} \\
& + \nu_1 I_{HD}^* + \xi_1 I_H^* - A_4 T_H^* - \nu_1 I_{HD}^* \frac{T_H}{T_H^*} - \xi_1 I_H^* \frac{T_H}{T_H^*} + A_4 T_H + \nu_2 I_{HD}^* \\
& + \xi_2 I_D^* - A_5 T_D^* - \nu_2 I_{HD}^* \frac{T_D}{T_D^*} - \xi_2 I_D^* \frac{T_D}{T_D^*} + A_5 T_D + \alpha_1 T_H^* \\
& (\alpha_2 T_D^* - A_6 T_{HD}^*) - \alpha_1 T_H^* \frac{T_{HD}}{T_{HD}^*} - \alpha_2 T_D^* \frac{T_{HD}}{T_{HD}^*} + 6A_6 T_{HD}^*
\end{aligned}$$

let $\frac{dL}{dt} = M - N$

where M are the positive values and N the negative values then, grouping negative and positive terms gives,

$$\begin{aligned}
M = & \wedge + \gamma_{2d}T^* + \lambda_H I_H^* S + \lambda_D I_D^* S + \mu S + q_1 \lambda_H S^* I_H^* + q_1 \gamma_{1d} T_{HD}^* + q_1 A_1 I_H \\
& + q_2 \lambda_D S^* I_D^* + q_3 \omega_1 I_H^* + q_3 \omega_2 I_D^* + q_3 A_3 I_{HD} + q_4 \nu_1 I_{HD}^* + \xi_1 I_H^* \\
& + q_4 A_4 T_H + q_5 \nu_2 I_{HD}^* + q_5 \xi_2 I_D^* + q_5 A_5 T_D + q_6 \alpha_1 T_H^* + q_6 \alpha_2 T_D^* + q_6 A_6 T_{HD}^*
\end{aligned}$$

$$\begin{aligned}
N = & -\lambda_H S^* I_H^* - \lambda_D S^* I_D^* - \mu S - \frac{S}{S^*} \wedge - \gamma_{2d} T_D^* \frac{S}{S^*} - q_1 A_1 I_H^* - q_1 \lambda_H S^* I_H \\
& - \gamma_{1d} T_{HD}^* \frac{I_H}{I_H^*} - q_2 A_2 I_D^* - q_2 \lambda_D S^* I_D - q_2 A_2 I_D - q_3 A_3 I_{HD}^* - q_3 \omega_1 I_H^* \frac{I_{HD}}{I_{HD}^*} \\
& - q_3 \omega_2 I_D^* \frac{I_{HD}}{I_{HD}^*} - A_4 T_H^* - q_4 \nu_1 I_{HD}^* \frac{T_H}{T_H^*} - q_4 \xi_1 I_H^* \frac{T_H}{T_H^*} - q_5 A_5 T_D^* - q_5 \nu_2 I_{HD}^* \frac{T_D}{T_D^*} \\
& - q_5 \xi_2 I_D^* \frac{T_D}{T_D^*} - q_6 A_6 T_{HD}^* - q_6 \alpha_1 T_H^* \frac{T_{HD}}{T_{HD}^*} - q_6 \alpha_2 T_D^* \frac{T_{HD}}{T_{HD}^*}
\end{aligned}$$

if $M < N$, then $\frac{dL}{dt} < 0$.

$\frac{dL}{dt} = 0$, if and only if $S = S^*, I_H = I_H^*, I_D = I_D^*, I_{HD} = I_{HD}^*, T_H = T_H^*, T_D = T_D^*$ and $T_{HD} = T_{HD}^*$.

The largest compact invariant set in $\{S, I_H, I_D, I_{HD}, T_H, T_D, T_{HD} \in: \frac{dL}{dt} = 0\}$

is a singleton E^* , where E^* is endemic equilibrium point. Therefore, the endemic equilibrium point is globally asymptotically stable in the invariant L if $M < N$ by Lasalle.,(1976).

3.3.10 Sensitivity analysis

This is examining the effect of control parameters on the basic reproduction number. We investigate using the Normalized forward sensitivity variable which is differentiable and depends on the control parameters. The sensitivity index of a control parameter on basic reproduction number is given by

$$\frac{\partial R_o}{\partial \phi} \times \frac{\phi}{R_o} \quad (33)$$

where

$$\phi(\wedge, \omega_1, \omega_2, \nu_2, \nu_2, \alpha_1, \alpha_2, \xi_1, \xi_2, \gamma_{1d}, \gamma_{2d}, \mu, \delta_h, \delta_{2d}, \delta_{hd}, \beta_1, \beta_2)$$

from analytical analysis, its evident that $\Lambda, \beta_1, \beta_2, \nu_2, \delta_{hd}, \gamma_{1d}, \gamma_{2d}, \alpha_1, \alpha_2$ have no effect on the basic reproduction number. The sensitivity indices for $(\omega_1, \omega_2, \nu_1, \xi_1, \xi_2, \mu, \delta_h, \delta_d)$ will be determined by numerical analysis.

4 Numerical simulations

4.0.1 Parameter Estimation

Table 4.1, shows some parameter values from the literature and others assumed for the purpose of illustration.

In 2015, Turkana county population was estimated at 1045579, comprising of 542,658 males (52 percent) and 502,921 females (48 percent)[KNBS, 2015]. Children below 15 years constituted 43 percent of the population, while youth aged 15-24 years constituted 24 percent of the population (2015 KNBS Population Projections).

We used the Kenyan demographic data to compute the death rates, HIV parameter values were obtained from the National AIDS Control Council (NACC) report of 2015, and the Kenya National Bureau of Statistics (KNBS) report of 2014 The initial values for some state variables were obtained from the Kenyan demographic data, Kenya-HIV-County-profiles 2016, NACADA 2017 and the NACC 2015 report although lack of documented data on drug and substance abuse in Turkana contributed to assumed values of some state variables and parameters on drugs

Female life expectancy in Kenya is 65.8 years and 61.1 years for male [WHO, 2015]. Therefore natural mortality rates, $\mu_f = \frac{1}{65.8} = 0.01519757$ and $\mu_m = \frac{1}{61.1} = 0.01636661$ respectively. We then calculate the natural mortality rate as the average of the two giving approximately $\mu = 0.0158$ per year.

We used the following variables;

$$\begin{aligned}
 S &= 50,000(\text{assumed}), & I_H &= 20396 \\
 I_D &= 30,000(\text{estimated}), & I_{HD} &= 10,000(\text{estimated}) \\
 TH &= 4684 & T_D &= 500(\text{assumed}) \\
 T_{HD} &= 5200(\text{assumed}).
 \end{aligned}$$

PARAMETER	VALUE	SOURCE
Λ	0.0397	World Bank 2017
β_1	0.04	Kenya HIV estimates(2015)
β_2	0.06	NACADA(2017)
λ_H	0.0039	Computed
λ_D	0.0116	Computed
ω_1	0.1700	Computed
ω_2	0.8333	Computed
ν_1	0.0390	Computed
ν_2	0.0042	Computed
α_1	0.9008	Estimated
α_2	0.0962	Estimated
ξ_1	0.2297	Computed
ξ_2	0.0050	Assumed
γ_{1d}	0.0199	Estimated
γ_{2d}	0.0005	Literature
μ	0.0200	WHO 2015
δ_d	0.015	Estimated
δ_h	0.0308	Computed
δ_{hd}	0.0229	Estimated

Table 3. parameter values

4.0.2 Numerical results

Susceptible

The figure below shows what happens in the susceptible population in the system with time. Since this happenings take a lot of time to be realised, the period of the simulation is taken as five years. The susceptible population decreases steadily with time and this explains why the graph in fig.2 increases as time goes on since increase in infected individuals decreases the susceptible.




Figure 1. Population of susceptible

HIV infected individuals

The rate at which susceptible individuals in fig.2 are getting infected with HIV increases steadily hence decreasing the susceptible population.




Figure 2. HIV infected individuals

Infected drug users

The population of drug users in fig.3 increases for a short while and gradually decreases. This can be viewed in the context that, the the rate at which individuals interact with those who use substances i.e susceptible drug users is lower compared to the rate of HIV infection.




Figure 3. Infected drug users, I_H

Dually infected individuals




Figure 4. Dually infected individuals, I_{HD}

Number of dually infected individuals in fig.4 above increases as the number of those infected singly with HIV and drug abuse habits increases too.

HIV infectives under treatment




Figure 5. HIV infectives under treatment, I_{HD}

Demand for HIV therapy treatment increases with increase in HIV infection in fig.2. This steady increase may be as a result of awareness information on importance of Antiretroviral therapy in suppressing the viral load leading to prolonged lifespan of HIV positive individuals.

Infected drug users on treatment

Figure(6) shows the rate at which drug abusers are seeking rehabilitation services or gradually getting informed on drug use dangers is increasing. Fig.3 explains this happenings since at a point in time, the number of those who use drugs reduces gradually. Decrease in the number of drug users corresponds to an increase in the number of people seeking drug abuse rehabilitation services or just avoiding the use of drugs.




Figure 6. Infected drug users on treatment, T_D

Dually infected individuals under treatment

The population seeking treatment for both HIV infection and drug abuse habits is increasing as the number of those dually infected also increases in fig.4. This could be attributed to the fact that, managing drug abuse habits helps in avoiding drug abuse consequences related to sexual health including decision making on use of condoms, having multiple sexual partners etc that can lead to getting sexually transmitted diseases including HIV/AIDS.




Figure 7. Dually infected individuals under treatment, T_{HD}




Figure 8. I_H (red) and I_D (black) Populations

From figure (8) above, as the number of HIV infectives increases, the population with drug abuse habits decreases showing that drug and substance abuse will have little impact on the spread of HIV/AIDS in Turkana County in the next five years.

5 Discussion and Conclusion

We designed a mathematical model on the transmission dynamics of HIV/AIDS in the context of drug and substance abuse and investigated its mathematical properties for assessing the impact of drug abuse on the transmission of HIV/AIDS in Turkana County. The disease-free equilibrium is shown to be globally asymptotically stable when the corresponding reproduction number is less than unity. Furthermore, a sensitivity analysis of the reproduction number to the level of drug and substance abuse is carried and it showed that drug misuse has the potential to increase disease transmission through the basic reproduction number.

BIBLIOGRAPHY

1. World Health Organization.(2015).HIV/AIDS Fact Sheet N360.
2. Odek-Ogunde M, Lore, W., Owiti, F. R. (2003) Risky behaviours among injecting drug users in Kenya. Paper presented at 14th International Conference on the Reduction of Drug Related Harm, April 2003, Chiang Mai, Thailand.
3. NACADA . Rapid situation assessment of the status of drug and substance abuse National Commission against Drug Abuse, Kenya. 2012. [Google Scholar]
4. Mushayabasa S, Tchuente J.M, Bhunu C.P., Ngarakana-Gwasira E. , Modeling gonorrhoea and HIV co-interaction.Biosystems 103, 27-37, (2011).
5. I Mardiyah 2012 Model matematika penyebaran infeksi HIV pada komunitas IDU.
6. E. White and C. Comiskey. Heroin epidemics, treatment and ODE modelling. Mathematical Biosciences., 208(1):312–324, 2007.
7. WHO . Sexually transmitted infections. Geneva: World Health Organisation; 2016.
8. NACC, 2016. <http://nacc.or.ke/wp-content/uploads/2016/11/Kenya-AIDS-Progress-Report-web.pdf>. Accessed 7 Feb 2017.
9. G. Thomas and E. M. Lungu, The influence of heavy alcohol consumption on HIV infection and progression, Journal of Biological Systems, 17 (2009), 615–712.
10. Blower SM, Hartel D, Dowlatabadi H, Anderson RM, May RM (1991) Drugs, sex and HIV: a mathematical model for New York City. Phil Trans R Soc Lond 321:171–187.
11. Thomas, G., and Lungu, E. M. (2010). A two-sex model for the influence of heavy alcohol consumption on the spread of HIV/AIDS. Mathematical Biosciences and Engineering, 7(4), 871-904.
12. Nacada. Rapid Situation Assessment of the Status of Drug and Substance Abuse. 2012;

-
13. Orwa, T. O. (2014). Modelling alcohol and methamphetamine co-abuse in the Western Cape Province of South Africa. Stellenbosch: Stellenbosch University, Stellenbosch University. Available from <http://scholar.sun.ac.za/handle/10019.1/3783> .

 14. Driessche and Watmough. Reproduction numbers and sub-thresho Diekmann and J. Heesterbeek. *Mathematical epidemiology of infectious diseases: model building, analysis and interpretation*. Wiley Series in Mathematical and Computational Biology, 1, 2000. Id endemic equilibria for compartmental models of disease transmission. *Mathematical Biosciences*, 180:29–48, 2002.

 15. Omondi, E., Mbogo, R., and Luboobi, L. (2018b). Mathematical modeling of the impact of testing, treatment and control of HIV transmission in Kenya. *Cogent Mathematics and Statistics*, 1475590.

 16. F. Nyabadza, J. B. Njagarah, and R. J. Smith. Modelling the dynamics of crystal meth ('tik') abuse in the presence of drug-supply chains in south africa. *Bulletin of Mathematical Biology*, 75(1):24–48, 2013.

 17. Kok, S., Rutherford, A. R., Gustafson, R., Barrios, R., Montaner, J. S., Vasarhelyi, K., on behalf of the Vancouver HIV Testing Program Modelling Group. (2015). Optimizing an HIV testing program using a system dynamics model of the continuum of care. *Health Care Management Science*, 18 (3), 334–362. doi:10.1007/s10729-014-9312-0

 18. Mukandavire, Z., Gumel, A. B., Garira, W., and Tchenche, J. M. (2009). Mathematical Analysis of a Model for HIV- malaria Co-Infection, 6(2), 333–362.

 19. Nyabadza, F. and Hove-Musekwa, S. D. (2010). From hero in epidemics to methamphetamine epidemics. Modelling substance abuse in a South African Province. *Mathematical Biosciences*, 225, 132–140. doi:10.1016/j.mbs.2010.03.002.

 20. Chersich MF, Luchters SMF, Malonza IM, Mwarogo P, Kingola N, Temmerman M: Heavy episodic drinking among Kenyan female sex workers is associated with unsafe sex, sexual violence and sexually transmitted infections. *Int J STD AIDS* 2007.

 21. Colfax, G. N., Mansergh, G., Guzman, R., Vittinghoff, E., Marks, G., Rader, M., Buchbinder, S. (2001). Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. *Journal of Acquired Immune Deficiency Syndromes* 28:373– 379.

-
22. WHO: Adherence to long-term therapies: evidence for action 2003, Report.
 23. Small, P. M., Shafer, R. W., Hopewell, P. C., Singh, S. P., Murphy, M. J., Desmond, E., ... and Schoolnik, G. K. (1993). Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *New England Journal of Medicine*, 328(16), 1137-1144.
 24. Orwa, T. O., and Nyabadza, F. (2019). Mathematical modelling and analysis of alcohol-methamphetamine co-abuse in the Western Cape Province of South Africa. *Cogent Mathematics and Statistics*, 6(1), 1641175.
 25. S. H. Ma, H. F. Huo and X. Y. Meng, Modelling alcoholism as a contagious dis-ease: A mathematical model with awareness programs and time delay, *Discrete Dynamics in Nature and Society*, 2015, 2015(2), 1–13.
 26. Center for Disease Control (CDC) (2000). HIV/AIDS. Frequently asked Questions on HIV/AIDS. Retrieved August 30, 2012, from www.cdcnpin.org/hiv/faq/preventionJitmCheryl, R., and Gert, R. (2003). *Introduction to Psychological*.
 27. Escandon, R., and Galvez, C. (2006). *Free from Addictions*. Madrid: Editorial safeliz.
 28. Kiemo K, Michuki G. Alcohol use in Central Province of Kenya. A baseline survey on magnitude, causes and effects from the perspective of community members and individual users, NACADA Report, December 2010. Retrieved on March 28 from <http://www.nacada.go.ke/wp-content/uploads/2011/02/central-servey.pdf>.
 29. Parry, C.D.H., Plüddemann, A., Achrekar, A., Pule, M., Koopman, F., Williams, T., and Needle, R. (2006). "Rapid assessment of drug use and sexual HIV risk patterns in Durban, Pretoria and Cape Town, South Africa". Poster presented at the 68 th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD), June 2006. Scottsdale, Arizona.
 30. J.P. LaSalle *The Stability of Dynamical Systems* Regional Conference Series in Applied Mathematics, SIAM, Philedelphia (1976).
 31. WHO. *World health statistics*. 2015.

32. WorldBank. Crude birth rate for kenya. Federal Reserve Bank of St. Louise, 2017.

33. CDC-KENYA. Kenya 2015 annual report. Global Health-Kenya, 2015.

Appendix

Expressions for the parameters in table 4.1 are,

$$\left\{ \begin{array}{l} \lambda_H = \frac{\beta_1(I_H + \pi_1 I_{HD} + \pi_2 T_H + \pi_3 T_{HD})}{N} \\ \lambda_D = \frac{\beta_2(I_D + (1 - \pi_1) I_{HD} + \pi_4 T_D + (1 - \pi_3) T_{HD})}{N} \\ \omega_1 = \frac{I_H}{I_{HD}}, \omega_2 = \frac{I_D}{I_{HD}}, \nu_1 = \frac{I_{HD}}{T_H}, \nu_2 = \frac{I_{HD}}{T_D}, \\ \alpha_1 = \frac{T_H}{T_{HD}}, \alpha_2 = \frac{T_D}{T_{HD}}, \xi_1 = \frac{T_H}{I_H}, \xi_2 = \frac{T_H}{I_H}, \\ \gamma_{1d} = \frac{T_{HD}}{I_H + T_H}, \gamma_{2d} = \frac{T_D}{S}. \end{array} \right. \quad (34)$$